Project Grant R21AG087400
- This $342,934.65 project grant from the Department of Health and Human Services National Institutes of Health National Institute on Aging, under the Aging Research program (CFDA 93.866), will fund research into acyl chain remodeling and regional lipid dysregulation in Alzheimer's disease. The Trustees of Columbia University in the City of New York, doing business as Health Sciences Division, will analyze lipid composition in brain regions susceptible to Alzheimer's disease, such as the...
- Federal Grant Award Summary The National Institute on Aging (NIA) awarded a $452,375 Project Grant to Columbia University's Health Sciences Division on January 1, 2026, under the Aging Research program (CFDA 93.866) to investigate astrocyte-mediated mechanisms in Lewy Body Dementia (LBD). This two-year research initiative, concluding December 31, 2027, focuses on understanding how deficiency in glucocerebrosidase (GCase), encoded by the GBA1 gene, contributes to LBD pathophysiology using mouse...
- This $427,625 Project Grant was awarded by the National Institute on Aging (NIA) under the Aging Research Federal Grant Program (CFDA 93.866). The grant was awarded to The Washington University in St. Louis to support research evaluating novel transcription factors that regulate astrocyte identity, reactivity, and their roles in the pathogenesis of Alzheimer's disease (AD) and Parkinson's disease (PD). The research aims to systematically evaluate 10 candidate transcription factors identified...
- The San Diego Biomedical Research Institute received a $541,750 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), effective May 15, 2026 through April 30, 2028. The award supports the discovery of novel autophagy-activating molecules designed to enhance cellular protein clearance mechanisms in neuronal models of dementia, including Alzheimer's...
- Federal Project Grant Award Summary The National Institute on Aging (NIA) awarded a $421,225 Project Grant to the University of Texas Health Science Center at Houston, effective July 1, 2026 through June 30, 2028, under the Aging Research program (CFDA 93.866). The grant supports research using Drosophila vitellogenic oocytes as an in vivo model system to elucidate the regulatory mechanisms of low-density lipoprotein receptor-related protein 1 (LRP1), a key regulator of lipid metabolism and...
- Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded The Leland Stanford Junior University a Project Grant of $122,526 on May 15, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). This basic research award funds the development and utilization of novel adult human brain organoids using an air-liquid interface (ALI) culture system to investigate the mechanisms of Alzheimer's Disease (AD)...
- Grant Award Summary Vanderbilt University received a $421,250 Project Grant from the National Institute on Aging under the Aging Research program (CFDA 93.866) for the period July 1, 2026 through June 30, 2028. The project, "State-Dependent Engineering of Therapeutic Functions in Reactive Astrocytes," focuses on developing a novel RNA-based therapeutic platform to address neuroinflammation in Alzheimer's disease. The core innovation is a programmable, orthogonal sensing circuit that...
- Federal Project Grant Award Summary The National Institute on Aging (NIA), operating under the Aging Research program (CFDA 93.866), awarded a $470,000 Project Grant to Trustees of Tufts College (doing business as Tufts University School of Medicine) for the period February 1, 2026 through January 31, 2028. The award supports research titled "Elucidating the Interplay Between AD Genetic Variants Using Human iPSC-Derived Brain Cells," which investigates the impact of single and...
- This Project Grant award from the National Institutes of Health's Aging Research program (CFDA 93.866) will support research to identify early transcriptional and pathological changes in brain regions vulnerable to Alzheimer's disease (AD). The $459,076 award, granted to Trustees of Boston University, will use single-nucleus RNA sequencing and targeted mass spectrometry to profile cell type-specific gene expression and tau/amyloid beta proteoforms in the transentorhinal cortex, entorhinal...
- Grant Award Summary The National Institute on Aging awarded a $335,880 Project Grant to Boston Children's Hospital on August 15, 2025, under the Aging Research program (CFDA 93.866) to support research elucidating the neuronal mechanisms underlying cognitive resilience to Alzheimer's disease (AD). The research will be completed by May 31, 2030. The project delivers research-based services focused on understanding why approximately 10-15% of individuals maintain normal cognitive function...
UNCOVERING DEMENTIA-RELATED LIPID ALTERATIONS AND MECHANISMS IN ASTROCYTES - PROJECT SUMMARY ALZHEIMER'S DISEASE (AD) AND RELATED DEMENTIAS (ADRD) ARE MULTIFACTORIAL DISORDERS WITH COMPLEX PATHOLOGICAL MECHANISMS. PROTEINOPATHY, NEURONAL IMPAIRMENTS, AND NEUROINFLAMMATION ARE WELL-KNOWN HALLMARKS OF ADRD. LIPID DYSREGULATION IS ALSO A PROMINENT FEATURE OF AD PATHOLOGY. GENES THAT CONTROL LIPID METABOLISM ARE IMPLICATED IN AD, AND PLASMA AND BRAIN LIPID LEVELS ARE ALTERED IN DISEASE. THERAPEUTICALLY MODIFYING LIPIDS MIGHT ALLEVIATE BEHAVIORAL AND COGNITIVE DECLINE AND RISK OF NEURODEGENERATIVE DISEASE, BUT ADDITIONAL STUDIES ARE NEEDED TO BETTER UNDERSTAND LIPID-RELATED MOLECULAR CHANGES AND THEIR EFFECTS ON BRAIN FUNCTION AND DISEASE. ASTROCYTES ARE ESSENTIAL FOR BRAIN LIPID HOMEOSTASIS DUE TO ASTROCYTIC ENRICHMENT OF LIPID-RELATED FACTORS AND THE DEPENDENCE OF NEURONS ON ASTROCYTES FOR LIPID TURNOVER AND VARIOUS LIPID-BASED PROCESSES. HOWEVER, THE EFFECTS OF DEMENTIA-ASSOCIATED PATHOLOGICAL FACTORS AND DISEASE CASCADES ON ASTROCYTIC LIPIDS HAVE NOT BEEN DEFINED. MOREOVER, HOW CHANGES IN ASTROCYTE LIPIDS ARE REGULATED AND HOW THEY INFLUENCE FOREBRAIN NEURONS IS UNCLEAR. FURTHER INVESTIGATIONS ARE REQUIRED TO DEFINE ASTROCYTIC LIPID SIGNATURES AND LIPID-BASED ALTERATIONS AND HOW THEY INFLUENCE NEURONAL FUNCTION AND VULNERABILITY TO DISEASE. OUR PRELIMINARY DATA SUGGEST THAT PROTEINOPATHY AND NEUROIMMUNE FACTORS INFLUENCE ASTROCYTE LIPID SYNTHESIS AND RELEASE, WHICH MAY AFFECT ASTROCYTIC-NEURONAL INTERACTIONS AND NEURONAL HEALTH IN AGING AND DISEASE. BASED ON OUR NOVEL RESULTS, WE HYPOTHESIZE THAT AD-RELATED PROTEINOPATHY AND NEUROIMMUNE SIGNALING INDUCE MALADAPTIVE CHANGES IN ASTROCYTIC LIPID METABOLISM AND RELEASE THAT PROMOTE NEURONAL VULNERABILITY IN DEMENTIA. IN THE PROPOSED R21 STUDY, WE WILL USE LIPIDOMICS AND OTHER ADVANCED APPROACHES IN MOUSE MODELS TO CHARACTERIZE THE SPATIOTEMPORAL ALTERATIONS IN ASTROCYTE LIPIDS DURING AGING AND DISEASE (AIM 1) AND INVESTIGATE HOW ALTERATIONS IN ASTROCYTIC LIPIDS ARE REGULATED AND MAY PROMOTE NEURONAL IMPAIRMENTS AND VULNERABILITY TO DISEASE (AIM 2). WE WILL PERFORM INNOVATIVE LIPIDOMIC PROFILING IN ASTROCYTES AT DIFFERENT AGES AND ACROSS BRAIN REGIONS, WHICH WILL ADDRESS PREVIOUSLY UNDERAPPRECIATED MOLECULAR SIGNATURES IN ASTROCYTES. WE WILL ALSO USE A NOVEL APPROACH OF SPATIAL LIPIDOMICS TO RESOLVE LIPID-BASED CHANGES ACROSS BRAIN REGIONS AND USE ISOLATED MOUSE ASTROCYTES AND HUMAN IPSC-DERIVED ASTROCYTES TO IDENTIFY CELL-AUTONOMOUS EFFECTS AND MOLECULAR MECHANISMS THAT REGULATE ASTROCYTE LIPIDS AND LIPID-BASED ASTROCYTIC-NEURONAL INTERACTIONS. IN SUMMARY, THE PROPOSED STUDY SEEKS TO ELUCIDATE NOVEL LIPID SIGNATURES AND MOLECULAR MECHANISMS ASSOCIATED WITH ADRD, WHICH MAY REVEAL NEW THERAPEUTIC STRATEGIES FOR NEURODEGENERATIVE DISORDERS.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $466.1k | 5/14/24 |